AbbVie gets option on early Argenx cancer drug for $40 million

(Reuters) - AbbVie has acquired an option on an early-stage immuno-oncology drug from biotech company Argenx, giving the U.S. drugmaker access to a treatment with the potential to block a biological pathway that allows cancers to grow.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro